GlaxoSmithKline has entered a five-year collaboration with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR). The new laboratory will explore how gene mutations cause disease and develop new technologies using CRISPR, the most powerful tool in functional genomics, to rapidly accelerate the discovery of new medicines.   Dr. Hal Barron, chief scientific officer and president, R&D, GSK said: “Technology ...